Table 1.
Summary of reviewed studies and case reports on topical imiquimod
| Reference | Treatment groups | Number of lesions | Regimen | Results (at last follow-up) | Follow-up | Notes |
|---|---|---|---|---|---|---|
| Patel et al | Imiquimod 5% | 15 | Imiquimod 5% once daily for 16 weeks | 75% (9/12) | 9 months | 3 drop outs in the imiquimod group |
| Placebo (vehicle) | 16 | 0% CR | ||||
| Mackenzie-Wood et al | Imiquimod | 16 | Imiquimod 5% once daily for 16 weeks | 93% CR (13/14) | 6 months | 2 patients died from unrelated illness |
| Smith et al | Imiquimod 5% + 5-FU | 5 | Alternating Imiquimod 3 × and 5-FU 4 × per week for 5–7 weeks | 100% CR | 3–15 months | Renal transplant recipients |
| Smith et al | Imiquimod 5% + sulindac + valacyclovir | 5 | Imiquimod 5% 3 ×/week + sulindac 200 mg 2 ×/d + valacyclovir 1000 mg/d for 16 weeks | 100% CR | 5–14 months | Patients with chronic lymphatic leukemia |
| Muzio et al | Imiquimod 5% | 3 | Imiquimod 5% under occlusive dressing (changed every 3 days) for 60–75 days | 100% CR | 267–423 days | Systemic side effects in 2 patients |
| Prinz et al | Imiquimod 5% | 4 | Imiquimod 5% 3 ×/week (daily application in case of no clinical response after 2 weeks) | 75% CR (3/4) | 6 months | Organ transplant recipients; 1 recurrence after 10 months |
Abbreviations: CR, complete response; FU, 5-fluorouracil.